162 related articles for article (PubMed ID: 21867691)
1. Biomarker signatures of mitochondrial NDUFS3 in invasive breast carcinoma.
Suhane S; Berel D; Ramanujan VK
Biochem Biophys Res Commun; 2011 Sep; 412(4):590-5. PubMed ID: 21867691
[TBL] [Abstract][Full Text] [Related]
2. Suppression of mitochondrial complex I influences cell metastatic properties.
He X; Zhou A; Lu H; Chen Y; Huang G; Yue X; Zhao P; Wu Y
PLoS One; 2013; 8(4):e61677. PubMed ID: 23630608
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer.
Wang P; Cheng X; Fu Z; Zhou C; Lu W; Xie X
Int J Gynecol Cancer; 2013 May; 23(4):622-9. PubMed ID: 23446378
[TBL] [Abstract][Full Text] [Related]
4. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
[TBL] [Abstract][Full Text] [Related]
5. Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma.
Ellinger J; Poss M; Brüggemann M; Gromes A; Schmidt D; Ellinger N; Tolkach Y; Dietrich D; Kristiansen G; Müller SC
Clin Genitourin Cancer; 2017 Aug; 15(4):e551-e562. PubMed ID: 28063846
[TBL] [Abstract][Full Text] [Related]
6. Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival.
Davies JQ; Lin HH; Stacey M; Yona S; Chang GW; Gordon S; Hamann J; Campo L; Han C; Chan P; Fox SB
Oncol Rep; 2011 Mar; 25(3):619-27. PubMed ID: 21174063
[TBL] [Abstract][Full Text] [Related]
7. CD133 expressionand clinicopathologic significance in benign and malignant breast lesions.
Liu TT; Li XF; Wang L; Yang JL
Cancer Biomark; 2020; 28(3):293-299. PubMed ID: 32390595
[TBL] [Abstract][Full Text] [Related]
8. NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer.
Lund RR; Leth-Larsen R; Caterino TD; Terp MG; Nissen J; Lænkholm AV; Jensen ON; Ditzel HJ
Mol Cell Proteomics; 2015 Nov; 14(11):2988-99. PubMed ID: 26351264
[TBL] [Abstract][Full Text] [Related]
9. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer.
Lynch BJ; Guinee DG; Holden JA
Hum Pathol; 1997 Oct; 28(10):1180-8. PubMed ID: 9343325
[TBL] [Abstract][Full Text] [Related]
10. Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.
Giaginis C; Sampani A; Kotta-Loizou I; Giannopoulou I; Danas E; Politi E; Tsourouflis G; Kouraklis G; Patsouris E; Keramopoulos A; Nakopoulou L; Theocharis S
Pathol Oncol Res; 2018 Jul; 24(3):631-640. PubMed ID: 28808873
[TBL] [Abstract][Full Text] [Related]
11. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
12. Potential Indexing of the Invasiveness of Breast Cancer Cells by Mitochondrial Redox Ratios.
Sun N; Xu HN; Luo Q; Li LZ
Adv Exp Med Biol; 2016; 923():121-127. PubMed ID: 27526133
[TBL] [Abstract][Full Text] [Related]
13. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
[TBL] [Abstract][Full Text] [Related]
14. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.
Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
Breast Cancer Res; 2007; 9(6):R89. PubMed ID: 18096060
[TBL] [Abstract][Full Text] [Related]
16. Microcysts and breast cancer: a study of biological markers in archival biopsy material.
Tran DD; Lawson JS
Breast Cancer Res Treat; 2002 Oct; 75(3):213-20. PubMed ID: 12353810
[TBL] [Abstract][Full Text] [Related]
17. Response on: reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer.
Piek JM
Int J Gynecol Cancer; 2013 Oct; 23(8):1348. PubMed ID: 24257547
[No Abstract] [Full Text] [Related]
18. Role of miR-139 as a surrogate marker for tumor aggression in breast cancer.
Dai H; Gallagher D; Schmitt S; Pessetto ZY; Fan F; Godwin AK; Tawfik O
Hum Pathol; 2017 Mar; 61():68-77. PubMed ID: 27864119
[TBL] [Abstract][Full Text] [Related]
19. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
20. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
